Compare MSD & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSD | SLGL |
|---|---|---|
| Founded | 1993 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 159.7M |
| IPO Year | N/A | 2018 |
| Metric | MSD | SLGL |
|---|---|---|
| Price | $7.93 | $73.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 70.2K | 27.6K |
| Earning Date | 01-01-0001 | 11-20-2025 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,970,000.00 |
| Revenue This Year | N/A | $122.71 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $6.11 | $4.02 |
| 52 Week High | $7.46 | $76.80 |
| Indicator | MSD | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 86.44 | 59.91 |
| Support Level | $7.83 | $62.08 |
| Resistance Level | $7.90 | $76.80 |
| Average True Range (ATR) | 0.05 | 6.94 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 100.00 | 63.92 |
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.